News

The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to…

The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.

The American Thoracic Society (ATS) Foundation Research Program and the Foundation for Sarcoidosis Research (FSR) have awarded a Foundation Partner Grant to Nicholas Arger, MD, at the University of California San Francisco, to study the role of a specific population of immune cells in sarcoidosis-related…

aTyr Pharma announced a collaboration and license agreement with Kyorin Pharmaceutical to develop and commercialize ATYR1923, its potential disease-modifying treatment for those with interstitial lung diseases (ILDs), including pulmonary sarcoidosis, in Japan. ATYR1923 is a fusion protein that contains a portion of a human antibody linked to…

The transplantation program at Stanford Medicine has hit a milestone with its 1,000th procedure — performed on a 54-year-old woman with sarcoidosis. The surgery, carried under the Heart-Lung & Lung Transplantation Program at Stanford Health Care, is now part of the 750 lung transplants and 250 heart-lung…

While sarcoidosis affecting the testicles is rare, it can be a cause of infertility in men, according to a new case report. The report, “Sarcoidosis is a rare cause of infertility: A case report,” was published in Urology Case Reports. Sarcoidosis is characterized by the…

ATYR1923, aTyr Pharma’s lead investigational therapy for pulmonary sarcoidosis, is safe and well-tolerated, according to interim data from a Phase 1b/2a clinical trial. ATYR1923 is a first-in-class disease-modifying therapy  in development for the treatment of different types of interstitial lung diseases…

The lungs of patients with sarcoidosis are burdened with a more active subset of immune T-cells, called mucosal-associated invariant T (MAIT) cells, a study reports. The activity of these MAIT cells correlates with worse disease, supporting their potential as therapeutic targets, the researchers said. The study, “…

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.

Intermediate monocytes, a type of immune cell, may contribute to the development and progression of sarcoidosis through the production of TARC — a molecule that attracts other specific immune cells linked to inflammation, according to a small study. These findings point to intermediate monocytes and TARC as potential treatment targets…